CLEARPOINT NEURO INC (CLPT)

US18507C1036 - Common Stock

15.89  +0.35 (+2.25%)

After market: 15.89 0 (0%)

Fundamental Rating

4

Overall CLPT gets a fundamental rating of 4 out of 10. We evaluated CLPT against 187 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for CLPT as it has an excellent financial health rating, but there are worries on the profitability. CLPT is valued quite expensive, but it does show an excellent growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

CLPT had negative earnings in the past year.
In the past year CLPT has reported a negative cash flow from operations.
In the past 5 years CLPT always reported negative net income.
In the past 5 years CLPT always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -45.15%, CLPT is not doing good in the industry: 63.98% of the companies in the same industry are doing better.
CLPT's Return On Equity of -62.57% is in line compared to the rest of the industry. CLPT outperforms 44.09% of its industry peers.
Industry RankSector Rank
ROA -45.15%
ROE -62.57%
ROIC N/A
ROA(3y)-34.46%
ROA(5y)-34.56%
ROE(3y)-59.48%
ROE(5y)-116.8%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CLPT has a Gross Margin of 60.38%. This is comparable to the rest of the industry: CLPT outperforms 58.60% of its industry peers.
CLPT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CLPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.38%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.19%
GM growth 5Y-3.22%

More info and screens

7

2. Health

2.1 Basic Checks

CLPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLPT has more shares outstanding
The number of shares outstanding for CLPT has been increased compared to 5 years ago.
CLPT has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 17.03 indicates that CLPT is not in any danger for bankruptcy at the moment.
The Altman-Z score of CLPT (17.03) is better than 93.01% of its industry peers.
There is no outstanding debt for CLPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 17.03
ROIC/WACCN/A
WACC9.14%

2.3 Liquidity

CLPT has a Current Ratio of 4.54. This indicates that CLPT is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.54, CLPT is doing good in the industry, outperforming 74.19% of the companies in the same industry.
CLPT has a Quick Ratio of 3.61. This indicates that CLPT is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.61, CLPT is doing good in the industry, outperforming 73.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.54
Quick Ratio 3.61

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.33% over the past year.
Looking at the last year, CLPT shows a very strong growth in Revenue. The Revenue has grown by 36.39%.
The Revenue has been growing by 26.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)23.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)36.39%
Revenue growth 3Y23.14%
Revenue growth 5Y26.65%
Sales Q2Q%40.96%

3.2 Future

The Earnings Per Share is expected to grow by 12.03% on average over the next years. This is quite good.
Based on estimates for the next years, CLPT will show a very strong growth in Revenue. The Revenue will grow by 39.76% on average per year.
EPS Next Y24.53%
EPS Next 2Y15.86%
EPS Next 3Y12.03%
EPS Next 5YN/A
Revenue Next Year34.32%
Revenue Next 2Y27.94%
Revenue Next 3Y39.76%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

CLPT's earnings are expected to grow with 12.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.86%
EPS Next 3Y12.03%

More info and screens

0

5. Dividend

5.1 Amount

CLPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEARPOINT NEURO INC

NASDAQ:CLPT (1/3/2025, 8:00:01 PM)

After market: 15.89 0 (0%)

15.89

+0.35 (+2.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)01-06 2025-01-06/amc
Inst Owners30.42%
Inst Owner Change-4.23%
Ins Owners4.59%
Ins Owner Change-0.54%
Market Cap438.25M
Analysts84.44
Price Target16.66 (4.85%)
Short Float %2.93%
Short Ratio3.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.21%
Min EPS beat(2)-1.81%
Max EPS beat(2)20.24%
EPS beat(4)3
Avg EPS beat(4)11.06%
Min EPS beat(4)-1.81%
Max EPS beat(4)20.24%
EPS beat(8)5
Avg EPS beat(8)0.76%
EPS beat(12)8
Avg EPS beat(12)3.79%
EPS beat(16)10
Avg EPS beat(16)3.49%
Revenue beat(2)2
Avg Revenue beat(2)3.73%
Min Revenue beat(2)2.36%
Max Revenue beat(2)5.11%
Revenue beat(4)4
Avg Revenue beat(4)4.18%
Min Revenue beat(4)2.19%
Max Revenue beat(4)7.08%
Revenue beat(8)5
Avg Revenue beat(8)0.19%
Revenue beat(12)7
Avg Revenue beat(12)0.89%
Revenue beat(16)9
Avg Revenue beat(16)2.04%
PT rev (1m)0%
PT rev (3m)38.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.25%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.4
P/FCF N/A
P/OCF N/A
P/B 15.11
P/tB 15.44
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS1.1
BVpS1.05
TBVpS1.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.15%
ROE -62.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.38%
FCFM N/A
ROA(3y)-34.46%
ROA(5y)-34.56%
ROE(3y)-59.48%
ROE(5y)-116.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.19%
GM growth 5Y-3.22%
F-Score5
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.92%
Cap/Sales 0.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.54
Quick Ratio 3.61
Altman-Z 17.03
F-Score5
WACC9.14%
ROIC/WACCN/A
Cap/Depr(3y)251.1%
Cap/Depr(5y)202.61%
Cap/Sales(3y)3.68%
Cap/Sales(5y)3.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y24.53%
EPS Next 2Y15.86%
EPS Next 3Y12.03%
EPS Next 5YN/A
Revenue 1Y (TTM)36.39%
Revenue growth 3Y23.14%
Revenue growth 5Y26.65%
Sales Q2Q%40.96%
Revenue Next Year34.32%
Revenue Next 2Y27.94%
Revenue Next 3Y39.76%
Revenue Next 5YN/A
EBIT growth 1Y15.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.25%
EBIT Next 3Y24.6%
EBIT Next 5YN/A
FCF growth 1Y48.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.68%
OCF growth 3YN/A
OCF growth 5YN/A